While India is battling with the second wave of COVID-19, the government is now facing the challenge of vaccinating its billion-plus population to fight against the virus which has cost the lives of millions. So far the Government of India has approved six COVID 19 vaccines that would be made available in the country in the coming months in order to accomplish the mission.
Covishield and Covaxin are the primary vaccines being administered in India and if reports are to go by, India might have access to six COVID-19 vaccines, being locally developed by the end of 2021. Speeding up the development of domestically produced vaccines will not just accelerate the availability of vaccines in India, but also will save costs.
Here’s a list of the homegrown vaccines being worked on in India.
Corvabex by Biological E:
Biological E’s Corvabex has been on air since the government officials announced the purchase of around thirty crore doses from the company. Claiming to be one of the cheapest and economical vaccines in the world, the vaccine has been indigenously produced.
PTX-COVID19-B by Biological E:
Biological E will oversee the development of India’s first mRNA vaccine and this is under development by Canada-based Providence Therapeutics Holdings.
The Ahmedabad-based domestic drugmaker Zydus Cadilia vaccine is under development could also be the second homegrown made for kids. The company along with Bharat Biotech is currently testing its vaccines on kids in the age group of 12-18 years.
Sputnik V manufactured by Dr Reddy’s Laboratories
Hyderabad-based pharma major, Dr Reddy has received emergency use authorization for the marketing and production of the Russian COVID-19 vaccine, Sputnik V in India in the month of April. While the soft launch has already taken place, the production would be scaled in the coming weeks.
Mynvax’s COVID vaccine
Mynvax, a Bengaluru-based start-up announced that it would work on a vaccine that uses a different approach involving a protein-based vaccine. This has been done in collaboration with the IISC. The pre-clinical trials are on at the moment.